Washington, Aug 08 (ANI): Researchers have reported positive results from a phase 2 clinical trial for a drug designed to block the advance of type 1 diabetes in its earliest stages.
Patients who benefited most were those who still had relatively good control of their blood sugar levels and only a moderate need for insulin injections when the trial began.
With the experimental drug, teplizumab, they were able to maintain their level of insulin production for the full two years, which is longer than with most other drugs tested against the disease.
The clinical trial was led by Kevan Herold, MD, PhD, a professor of immunobiology and deputy director for translational science at Yale University.
The researchers said that the results underscore the importance of diagnosing and treating diabetes in its earliest stages.
Teplizumab is one of the number drugs under active investigation to control autoimmune reactions. It uses an antibody targeted against a molecule called CD3 to bind to the immune system1s T-cells and restrain them from attacking beta cells.
The study focused on 52 participants, most of whom were less than 14 years old, who had been diagnosed with "new-onset type 1 diabetes" within eight weeks of the trial's start.
All 52 were treated with the experimental drug for two weeks at diagnosis and again one year later, and their capacity to produce their own insulin to control their blood sugar was compared with a non-treated group.
The study is published online in the journal Diabetes. (ANI)